Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Edurant

EDURANT 25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10

HOS-213959 · Präparat HOS-155234

9  HMG CO-A REDUCTASE INHIBITORS Atorvastatin*# atorvastatin AUC ↔ No dose adjustment is required. 40 mg once daily atorvastatin Cmin ↓ 15% atorvastatin Cmax ↑ 35% rilpivirine AUC ↔ rilpivirine Cmin ↔ rilpivirine Cmax ↓ 9% PHOSPHODIESTERASE TYPE 5 (PDE-5) INHIBITORS Sildenafil*# sildenafil AUC ↔ No dose adjustment is required. 50 mg single dose sildenafil Cmin NA sildenafil Cmax ↔ rilpivirine AUC ↔ rilpivirine Cmin ↔ rilpivirine Cmax ↔ Vardenafil Not studied. No dose adjustment is required. Tadalafil * The interaction between rilpivirine and the medicinal product was evaluated in a clinical study. All other drug-drug interactions shown are predicted. # This interaction study has been performed with a dose higher than the recommended dose for rilpivirine assessing the maximal effect on the co-administered medicinal product. The dosing recommendation is applicable to the recommended dose of rilpivirine of 25 mg once daily. † This interaction study has been performed with a dose higher than the recommended dose for rilpivirine.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) atorvastatin (HOS-086304) sildenafil (HOS-086162) vardenafil (HOS-086163)